A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called \u2018CanPredict\u2019, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.
New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient\u2019s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.
Health and care research in Oxford is to receive \u00a3122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city\u2019s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).
Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.
A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin\u2019s mechanism of action when taken as a preventative for mTP53-driven cancers.
A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.
Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.
COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.
Researchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.
A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.
Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.
Oxford researchers will lead a \u00a32m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.
A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.
Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.
![\"Hands](\"https://www.oncology.ox.ac.uk/news/new-oxford-and-nottingham-developed-tool-uses-existing-health-records-to-predict-people2019s-risk-of-developing-lung-cancer-within-the-next-10-years/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n